Type 2 Diabetes Market

Executive Summary

Type 2 Diabetes Market was valued at US $32.33 billion in 2021 and is projected to grow at 8.44% CAGR over the forecast period to reach US $52.57 billion by 2027. Type 2 Diabetes Market represented US $4.84 billion opportunity over 2019-2021 and estimated to create US $20.24 billion opportunity in 2027 over 2021.

Type 2 Diabetes from Consainsights analyses the Type 2 Diabetes Market in the Life Sciences industry over the forecast period to 2027.

Type 2 Diabetes research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Type 2 Diabetes segmentation includes Drug Class, Application, Region and Geography.

Based on the Drug Class, the Type 2 Diabetes analysis covers DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS, GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS, THIAZOLIDINEDIONES, ALPHA-GLUCOSIDASE INHIBITORS, SULFONYLUREAS & OTHER INSULIN SECRETAGOGUES, BIGUANIDES, SODIUM–GLUCOSE COTRANSPORTER 2 INHIBITORS.

In Drug Class segment, DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS segment has highest cagr growth of 7.47%.

Based on the Application, the Type 2 Diabetes analysis covers GLYCEMIC CONTROL, CARDIOVASCULAR SAFETY, HYPOGLYCEMIA AVOIDANCE, OTHERS.

In Application segment, GLYCEMIC CONTROL segment has highest cagr growth of 7.47%.

Based on the Region, the Type 2 Diabetes analysis covers NORTH AMERICA, EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, NORTH AMERICA segment has highest cagr growth of 7.47%.

Based on the region, the Type 2 Diabetes analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include ELI LILLY AND CO., SANOFI AVENTIS A/S, NOVO NORDISK, MERCK & CO., INC., CHUGAI PHARMACEUTICAL CO., BRISTOL-MYERS SQUIBB, PFIZER INC., BAYER AG, GLAXOSMITHKLINE PLC., ASTRAZENECA PLC and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Drug Class

Introduction

In 2021, DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS segment has the highest revenue of US $13.50 billion and is expected to grow at CAGR of 7.47% by 2027 DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS segment has highest cagr growth of 7.47%.

DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS

DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS segment was valued at US $11.48 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $21.96 billion by 2027. DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS segment represented US $2.02 billion opportunity over 2019-2021 and estimated to create US $8.45 billion opportunity in 2027 over 2021.

GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS

GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS segment was valued at US $7.03 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $13.44 billion by 2027. GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS segment represented US $1.24 billion opportunity over 2019-2021 and estimated to create US $5.17 billion opportunity in 2027 over 2021.

THIAZOLIDINEDIONES

THIAZOLIDINEDIONES segment was valued at US $4.32 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $8.25 billion by 2027. THIAZOLIDINEDIONES segment represented US $0.76 billion opportunity over 2019-2021 and estimated to create US $3.18 billion opportunity in 2027 over 2021.

ALPHA-GLUCOSIDASE INHIBITORS

ALPHA-GLUCOSIDASE INHIBITORS segment was valued at US $2.41 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $4.60 billion by 2027. ALPHA-GLUCOSIDASE INHIBITORS segment represented US $0.42 billion opportunity over 2019-2021 and estimated to create US $1.77 billion opportunity in 2027 over 2021.

SULFONYLUREAS & OTHER INSULIN SECRETAGOGUES

SULFONYLUREAS & OTHER INSULIN SECRETAGOGUES segment was valued at US $1.12 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $2.14 billion by 2027. SULFONYLUREAS & OTHER INSULIN SECRETAGOGUES segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.82 billion opportunity in 2027 over 2021.

BIGUANIDES

BIGUANIDES segment was valued at US $0.74 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $1.42 billion by 2027. BIGUANIDES segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.55 billion opportunity in 2027 over 2021.

SODIUM–GLUCOSE COTRANSPORTER 2 INHIBITORS

SODIUM–GLUCOSE COTRANSPORTER 2 INHIBITORS segment was valued at US $0.40 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $0.76 billion by 2027. SODIUM–GLUCOSE COTRANSPORTER 2 INHIBITORS segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.29 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, GLYCEMIC CONTROL segment has the highest revenue of US $18.69 billion and is expected to grow at CAGR of 7.47% by 2027 GLYCEMIC CONTROL segment has highest cagr growth of 7.47%.

GLYCEMIC CONTROL

GLYCEMIC CONTROL segment was valued at US $15.90 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $30.40 billion by 2027. GLYCEMIC CONTROL segment represented US $2.80 billion opportunity over 2019-2021 and estimated to create US $11.70 billion opportunity in 2027 over 2021.

CARDIOVASCULAR SAFETY

CARDIOVASCULAR SAFETY segment was valued at US $6.05 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $11.56 billion by 2027. CARDIOVASCULAR SAFETY segment represented US $1.06 billion opportunity over 2019-2021 and estimated to create US $4.45 billion opportunity in 2027 over 2021.

HYPOGLYCEMIA AVOIDANCE

HYPOGLYCEMIA AVOIDANCE segment was valued at US $4.97 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $9.51 billion by 2027. HYPOGLYCEMIA AVOIDANCE segment represented US $0.88 billion opportunity over 2019-2021 and estimated to create US $3.66 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $0.57 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $1.09 billion by 2027. OTHERS segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.42 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, NORTH AMERICA segment has the highest revenue of US $15.52 billion and is expected to grow at CAGR of 7.47% by 2027 NORTH AMERICA segment has highest cagr growth of 7.47%.

NORTH AMERICA

NORTH AMERICA segment was valued at US $13.20 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $25.24 billion by 2027. NORTH AMERICA segment represented US $2.32 billion opportunity over 2019-2021 and estimated to create US $9.72 billion opportunity in 2027 over 2021.

EUROPE

EUROPE segment was valued at US $7.00 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $13.39 billion by 2027. EUROPE segment represented US $1.23 billion opportunity over 2019-2021 and estimated to create US $5.15 billion opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $7.26 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $13.89 billion by 2027. ASIA-PACIFIC segment represented US $1.28 billion opportunity over 2019-2021 and estimated to create US $5.35 billion opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $0.03 billion in 2019 and is projected to grow at 7.47% CAGR over the forecast period to reach US $0.05 billion by 2027. LAMEA segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.02 billion opportunity in 2027 over 2021.